Home›Legal›Tirzepatide in California
Tirzepatide in California: Legal Status & Provider Guide (2026)
Quick Answer
Tirzepatide is a prescription substance in the United States. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. The compounding shortage exemption expired in early 2025. Current federal law generally prohibits compounded tirzepatide outside of narrow exceptions. Providers offering compounded tirzepatide should have clear documentation of their legal basis. In California, compounding is governed by the California State Board of Pharmacy (CSBP). California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.
Federal Legal Status
FDA Approval Status
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). FDA declared the tirzepatide shortage resolved in December 2024.
Compounding Pharmacy Rules (Federal)
Compounded tirzepatide was broadly permitted during the shortage period. Following FDA's shortage resolution in December 2024, 503B outsourcing facilities had until February 18, 2025, and 503A pharmacies until March 19, 2025, to wind down compounding. As of mid-2025, compounded tirzepatide is generally prohibited except for narrow clinical exceptions under a valid prescription.
Also Known As
Mounjaro · Zepbound
Primary Research Areas
- Weight management
- Type 2 diabetes
- Metabolic health
- Insulin resistance
California Pharmacy Board & Compounding Rules
Compounding Overview
The California State Board of Pharmacy enforces strict compounding standards, often exceeding federal minimums. California has its own sterile compounding licensure category and requires all sterile compounding pharmacies to hold a specialty license. California pharmacies must comply with USP 797 (sterile) and USP 795 (non-sterile) standards. The California Medical Board also imposes strict telemedicine prescribing standards that affect peptide clinics operating as telehealth platforms serving California residents.
Notable Rules
- California requires a specialty sterile compounding license in addition to a standard pharmacy license.
- USP 797 and 795 compliance is mandatory for all California-licensed compounding pharmacies.
- The California Medical Board has specific guidance on prescribing practices for "off-label" and compounded medications.
- Out-of-state pharmacies must be licensed by CSBP to ship prescription compounds into California.
- California prohibits prescription dispensing without an established patient-provider relationship in most telehealth contexts.
Prescribing Requirements in California
California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.
About Tirzepatide
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. It has demonstrated significant efficacy in clinical trials for both glycemic control and weight reduction, with some studies showing superior weight loss compared to semaglutide.
For more research information, mechanism of action, and provider availability, see the Tirzepatide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded tirzepatide legal in 2026?
- FDA declared the tirzepatide shortage resolved in December 2024. Wind-down periods ended in Q1 2025. As of mid-2025, compounded tirzepatide is generally prohibited except for documented clinical exceptions. Patients should verify the legal basis with their provider.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight with a related condition. The drugs are chemically identical.
Tirzepatide Providers in California
No providers currently listed in California for Tirzepatide. Browse the full directory to find providers offering Tirzepatide.
Browse all Tirzepatide providers →Tirzepatide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Tirzepatide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .